Infliximab + methotrexate (mtx) (DrugBank: Infliximab, Methotrexate)
25 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
35 | Pemphigus | 0 |
37 | Generalised pustular psoriasis | 0 |
38 | Stevens-Johnson syndrome | 0 |
39 | Toxic epidermal necrolysis | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 0 |
42 | Polyarteritis nodosa | 0 |
43 | Microscopic polyangiitis | 0 |
45 | Eosinophilic granulomatosis with Polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
49 | Systemic lupus erythematosus | 0 |
50 | Dermatomyositis | 0 |
55 | Relapsing polychondritis | 0 |
56 | Behcet disease | 0 |
65 | Primary immunodeficiency | 0 |
84 | Sarcoidosis | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
98 | Eosinophilic gastrointestinal disease | 0 |
162 | Pemphigoid | 0 |
164 | Oculocutaneous albinism | 0 |
269 | Pyogenic arthritis | 0 |
271 | Ankylosing spondylitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00732875 (ClinicalTrials.gov) | August 2006 | 8/8/2008 | A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED) | A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part) | Arthritis, Rheumatoid | Biological: Infliximab + methotrexate (MTX) | Merck Sharp & Dohme Corp. | NULL | Completed | 18 Years | 75 Years | All | 92 | Phase 3 | NULL |